Kamunting Street Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kamunting Street Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-12,985	Closed	-$1.62M	–	17
2015 Q1	$1.62M	Sell	12,985 -10,815	-45%	-$1.15M	3.8%	8
2014 Q4	$2.15M	Sell	23,800 -3,400	-13%	-$283K	3.29%	10
2014 Q3	$1.96M	Buy	+27,200	New	+$1.79M	1.88%	17

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Kamunting Street Capital Management's BMRN Position: Q2 2015 in Review

Kamunting Street Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2015, closing a stake of 12,985 shares — an estimated $1.62M sold.

Kamunting Street Capital Management first reported a position in BMRN in Q3 2014 and held it in 3 quarters. The position peaked at $2.15M in Q4 2014. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

Kamunting Street Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Kamunting Street Capital Management sold 12,985 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $1.62M.
Kamunting Street Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 3 quarters.
Kamunting Street Capital Management's BioMarin Pharmaceuticals position peaked at $2.15M in Q4 2014.
392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on Kamunting Street Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.